| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Valemetostat (formerly known as DS-3201; DS-3201b; Ezharmia) is a first-in-class, investigational and oral EZH1/2 dual inhibitor with anticancer activity. It targets epigenetic regulation by inhibiting the EZH1, as well as EZH2 enzymes, which regulate gene expression by acting through histone methylation. A new drug application seeking the approval of valemetostat tosylate (DS-3201b) for use in the treatment of patients with relapsed/refractory adult T-cell leukemia/lymphoma (ATL) has been submitted to the Japanese Ministry of Health, Labour, and Welfare. As of September 2022, Valemetostat is the first dual EZH1/2 inhibitor approved for treatment of aggressive ATL in Japan. Valemetostat is being evaluated in Phase I clinical development for several types of NHLs, including ATL, peripheral T-cell lymphoma (PTCL) and B-cell lymphomas.
| ln Vitro |
With IC50 values <10 nM, valemetostat (1-1000 nM) substantially and selectively inhibits EZH1 and EZH2 [3]. H3K27me3 is efficiently eliminated by valemetostat (100 nM; 7 d) and unintentional increases in H3K27me3 are avoided [3]. Valemetostat (0.1-100 nM; 7 d) significantly suppresses H3K27me3 in lymphoma types that are sensitive to its effects in low doses [3].
|
|---|---|
| ln Vivo |
Following exercise training, valemetostat (0.01 mg/g; intraperitoneal injection; once) inhibits alterations in H3K27me3.
|
| Animal Protocol |
Animal/Disease Models: Male C57BL/6J mice, chronic, acute running or no exercise [1]
Doses: 0.01 mg/g Route of Administration: intraperitoneal (ip) injection; 0.01 mg/g; 30 minutes before the start of running. Experimental Results: H3K27me3 after exercise The levels were Dramatically increased, EZH1 levels were slightly diminished, EZH2 levels were upregulated, and phosphorylated AMPK levels were increased. Inhibits myonuclear H3K27me3 accumulation during training and leads to failure of adaptive changes. |
| References |
|
| Additional Infomation |
Valemetostat is an orally available selective inhibitor of the histone lysine methyltransferases enhancer of zeste homolog 1 (EZH1) and 2 (EZH2), with potential antineoplastic activity. Upon oral administration, valemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH1 and EZH2. Inhibition of EZH1/2 specifically prevents the methylation of lysine 27 on histone H3 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways, enhances transcription of certain target genes, and results in decreased proliferation of EZH1/2-expressing cancer cells. EZH1/2, histone lysine methyltransferase (HMT) class enzymes and catalytic subunits of the polycomb repressive complex 2 (PRC2), are overexpressed or mutated in a variety of cancer cells and play key roles in tumor cell proliferation, progression, stem cell self-renewal and migration.
|
| Molecular Formula |
C26H34CLN3O4
|
|---|---|
| Molecular Weight |
488.02
|
| Exact Mass |
487.223
|
| CAS # |
1809336-39-7
|
| Related CAS # |
Valemetostat tosylate;1809336-93-3
|
| PubChem CID |
126481870
|
| Appearance |
White to off-white solid powder
|
| Density |
1.26±0.1 g/cm3(Predicted)
|
| Boiling Point |
610.0±55.0 °C(Predicted)
|
| LogP |
4.4
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
34
|
| Complexity |
879
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC1=CC(=C(C(=O)N1)CNC(=O)C2=CC(=C3C(=C2C)O[C@@](O3)(C)C4CCC(CC4)N(C)C)Cl)C
|
| InChi Key |
SSDRNUPMYCFXGM-UYPAYLBCSA-N
|
| InChi Code |
InChI=1S/C26H34ClN3O4/c1-14-11-15(2)29-25(32)20(14)13-28-24(31)19-12-21(27)23-22(16(19)3)33-26(4,34-23)17-7-9-18(10-8-17)30(5)6/h11-12,17-18H,7-10,13H2,1-6H3,(H,28,31)(H,29,32)/t17-,18-,26-/m1/s1
|
| Chemical Name |
(2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide
|
| Synonyms |
DS3201Valemetostat DS-3201 DS 3201 DS-3201bEzharmia
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~70 mg/mL (~143.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (10.25 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (10.25 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3.5 mg/mL (7.17 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0491 mL | 10.2455 mL | 20.4910 mL | |
| 5 mM | 0.4098 mL | 2.0491 mL | 4.0982 mL | |
| 10 mM | 0.2049 mL | 1.0245 mL | 2.0491 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
